Aspergillosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 30: | Line 30: | ||
then 4 mg/kg IV/ PO Q12H | then 4 mg/kg IV/ PO Q12H | ||
|''' | |'''Ambisome''': | ||
5 mg/kg IV Q24H | 5 mg/kg IV Q24H | ||
Revision as of 19:04, 19 December 2012
|
Aspergillosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Aspergillosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Aspergillosis medical therapy |
|
Risk calculators and risk factors for Aspergillosis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Medical Therapy
Pharmacotherapy
- A fungus ball is usually not treated (with antifungal medicines) unless there is bleeding into the lung tissue. In that case, surgery is needed.
- Invasive aspergillosis is treated with several weeks of an antifungal drug called voriconazole. It can be given both oral and intravenous route. Amphotericin B, echinocandins, or itraconazole can also be used. Endocarditis caused by Aspergillus is treated by surgically removing the infected heart valves. Long-term antifungal therapy is also needed. [1]
- Allergic aspergillosis: Antifungal drugs alone do not help people with allergic aspergillosis. Allergic aspergillosis is treated with drugs that suppress the immune system (immunosuppressive drugs) -- most often oral prednisone.
The drugs amphotericin B, caspofungin, flucytosine, itraconazole, voriconazole are used to treat this fungal infection.[2]
| Characteristics of the Patient | Possible Pathogens | Preferred Treatment | Alternative Treatment |
| Patient with a hematologic
malignancy |
Aspergillus spp | Voriconazole
Loading dose:6 mg/kg IV/ PO Q12H times two doses, then 4 mg/kg IV/ PO Q12H |
Ambisome:
5 mg/kg IV Q24H |
References
- ↑ http://www.cdc.gov/fungal/aspergillosis/treatment.html
- ↑ Herbrecht R, Denning D, Patterson T, Bennett J, Greene R, Oestmann J, Kern W, Marr K, Ribaud P, Lortholary O, Sylvester R, Rubin R, Wingard J, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar P, Hodges M, Schlamm H, Troke P, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. (2002). "Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis". N Engl J Med. 347 (6): 408–15. PMID 12167683. Unknown parameter
|month=ignored (help)